0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Food & Water Human Health Effects Remediation Sign in to save

Therapeutic Effect of Prolyl Endopeptidase Inhibitor in High-fat Diet-induced Metabolic Dysfunction-associated Fatty Liver Disease

Journal of Clinical and Translational Hepatology 2023 4 citations ? Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count. Score: 45 ? 0–100 AI score estimating relevance to the microplastics field. Papers below 30 are filtered from public browse.
Jianbin Zhang, Meng-Ting Li, Shuang‐Zhe Lin, Yuqing Cheng, Jian‐Gao Fan, Yuanwen Chen

Summary

Studies in a high-fat diet mouse model of metabolic fatty liver disease found that increased prolyl endopeptidase activity during disease progression may drive the transition from simple steatosis to steatohepatitis, and that the PREP inhibitor KYP-2047 showed therapeutic potential.

Body Systems

These findings suggest that increased PREP activity/expression during MAFLD development might be a key factor in the transition from simple steatosis to steatohepatitis, and KYP-2047 might possess therapeutic potential for MAFLD treatment.

Sign in to start a discussion.

More Papers Like This

Article Tier 2

Adipose tissue as target of environmental toxicants: focus on mitochondrial dysfunction and oxidative inflammation in metabolic dysfunction-associated steatotic liver disease

This review examines how environmental toxicants, including micro and nanoplastics, target fat tissue and contribute to metabolic diseases like obesity, diabetes, and fatty liver disease. These pollutants disrupt mitochondria (the energy-producing parts of cells) and trigger a cycle of oxidative stress and inflammation that damages both fat tissue and the liver. The findings suggest that microplastic exposure could be one of several environmental factors contributing to the rising rates of metabolic disease worldwide.

Article Tier 2

Chronic Nanoplastic Exposure Promotes the Development and Progression of Metabolic Dysfunction‐Associated Steatotic Liver Disease

This study found that chronic exposure to nanoplastics promotes the development and worsening of metabolic dysfunction-associated steatotic liver disease (formerly known as fatty liver disease). Nanoplastics appear to increase vulnerability to liver disease progression. The finding is concerning because fatty liver disease is already widespread, and everyday nanoplastic exposure through food and water could be making it worse.

Article Tier 2

Disruption of hepatic metabolism in Lep KO mice.

Researchers found that polystyrene microplastics administered orally for nine weeks accumulated in liver tissue of leptin-knockout obese mice and induced histopathological liver alterations, including disruption of hepatic lipid, glucose, and amino acid metabolism.

Article Tier 2

Microplastics in metabolic dysfunction-associated steatotic liver disease: An emerging threat to liver health

This review examined emerging evidence linking microplastic exposure to the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). The authors found that microplastics detected in liver tissue can exacerbate hepatic inflammation, lipid accumulation, and oxidative stress through multiple mechanisms, adding a novel environmental risk factor to MASLD pathogenesis.

Article Tier 2

Polystyrene nanoplastics potentiate the development of hepatic fibrosis in high fat diet fed mice

Researchers found that polystyrene nanoplastics worsened liver damage in mice fed a high-fat diet by increasing oxidative stress, inflammation, and the infiltration of immune cells in liver tissue. The nanoplastic exposure accelerated the progression from fatty liver to hepatic fibrosis in the diet-induced model. The study suggests that nanoplastic exposure may compound the health risks associated with metabolic conditions affecting the liver.

Share this paper